Fluctuation of HCV viral load before seroconversion in a healthy volunteer blood donor

被引:24
作者
Fang, CT
Tobler, LH
Haesche, C
Busch, MP
Phelps, B
Leparc, G
机构
[1] Irwin Mem Blood Ctr, Blood Ctr Pacific, San Francisco, CA 94118 USA
[2] Amer Red Cross, Jerome H Holland Lab Biomed Sci, Rockville, MD USA
[3] Florida Blood Serv, St Petersburg, FL USA
[4] Chiron Corp, Emeryville, CA 94608 USA
关键词
D O I
10.1046/j.1537-2995.2003.00355.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Newly implemented NAT has been shown to be able to effectively identify HCV-positive blood donated during the preseroconversion period. STUDY DESIGN AND METHODS: EDTA-plasma pools of 24 donations were tested using an HIV-1/HCV multiplex NAT under an FDA-approved IND application. Samples in a positive pool were retested individually. Positive samples were further tested by two discriminatory assays to determine specific viral reactivity. Upon obtaining informed consent, seronegative donors with positive NAT results were enrolled into a follow-up study for risk factor analysis and laboratory testing. RESULTS: A donation by a 29 year old female was identified as HCV NAT-positive with negative serology and an elevated ALT. Her two previous donations, 5 and 12 months earlier, were both seronegative and with normal ALT. Her husband tested positive for HCV RNA. The donor remained seronegative for at least 36 days. The index donation had a viral RNA concentration of >500,000 copies per mL while the first seropositive sample was NAT-negative. Laboratory data on serial follow-up samples showed 100- to 1,000-fold fluctuations in viral load during a period of 48 days prior to seroconversion. CONCLUSIONS: This case suggests that, at least in some newly infected individuals, the HCV viral load can fluctuate dramatically prior to seroconversion, and that NAT, even on individual samples, will not totally prevent HCV transmission.
引用
收藏
页码:541 / 544
页数:4
相关论文
共 17 条
[1]   TO C OR NOT TO C - THESE ARE THE QUESTIONS [J].
ALTER, HJ .
BLOOD, 1995, 85 (07) :1681-1695
[2]  
Busch MP, 2001, BLOOD SAFETY IN THE NEW MILLENNIUM, P33
[3]  
BUSCH MP, 2001, POLICY ALTERNATIVES, P86
[4]  
COSTE J, 1999, TRANSFUSION S, V380, P83
[5]   Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population [J].
Dodd, RY ;
Notari, EP ;
Stramer, SL .
TRANSFUSION, 2002, 42 (08) :975-979
[6]  
EZZELL C, 1988, NATURE, V333, P195
[7]   The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies [J].
Farci, P ;
Shimoda, A ;
Coiana, A ;
Diaz, G ;
Peddis, G ;
Melpolder, JC ;
Strazzera, A ;
Chien, DY ;
Munoz, SJ ;
Balestrieri, A ;
Purcell, RH ;
Alter, HJ .
SCIENCE, 2000, 288 (5464) :339-344
[8]   Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA [J].
Giachetti, C ;
Linnen, JM ;
Kolk, DP ;
Dockter, J ;
Gillotte-Taylor, K ;
Park, M ;
Ho-Sing-Loy, M ;
McCormick, MK ;
Mimms, LT ;
McDonough, SH .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (07) :2408-2419
[9]  
McDonough SH, 1998, INFUSIONSTHERAPIE, V25, P164
[10]  
MOSLEY JW, 1999, ADV TRANSFUSION SAFE, P93